Adriamycin/cyclophosphamide combination chemotherapy: The importance of drug scheduling
article
The effect of adriamycin/cyclophosphamide combination chemotherapy was evaluated against a spectrum of transplantable tumours in mice (L1210 leukaemia, Lewis lung carcinoma and C22LR osteosarcoma) and critical normal tissue. Treatment was given either simultaneously or sequentially with a time interval of 24 hr. Drug synergism was observed in the treatment of L1210 when the two agents were administered simultaneously. In the solid tumour experiments, neither synergism nor schedule dependency could be demonstrated. From the bone marrow stem cell assays, it is concluded that simultaneous treatment is the least effective and therefore the least toxic schedule. Based on these data, it may be recommended that, in clinical cancer treatment, adriamycin and cyclophosphamide be given simultaneously and not sequentially. Chemicals/CAS: cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; Cyclophosphamide, 50-18-0; Doxorubicin, 23214-92-8
Topics
cyclophosphamidedoxorubicinanimal experimentblood and hemopoietic systembonecancer chemotherapycancer combination chemotherapydrug doseleukemia l 1210lung carcinomalymphatic systemmouseosteosarcomarespiratory systemtherapyAnimalCyclophosphamideDoxorubicinDrug Administration ScheduleDrug SynergismDrug Therapy, CombinationHematopoietic Stem CellsLeukemia L1210Lung NeoplasmsMiceNeoplasms, ExperimentalOsteosarcoma
TNO Identifier
228730
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 15(12), pp. 1503-1509.
Pages
1503-1509
Files
To receive the publication files, please send an e-mail request to TNO Repository.